Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation
Studies from both rat and mouse adult knockout animals showed that in liver, GST activity toward CDNB is 1750% lower when Nrf2 is silenced [28, 35, 45,46,47]
Several serious complications such as elevated liver enzymes, SOS, hemorrhagic cystitis, interstitial pneumonia and mucositis have been correlated to high-dose busulphan 10,11,12,15,33
Retrieved February 15, 2013
That is what this article delivers
